Press Release


February 11, 2016

Real Endpoints’ RxScorecard™ predicted launch failure of major new anti-cholestrol drugs

Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened.

read full press release >